Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S. Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? World J Radiol 2017; 9(2): 27-33 [PMID: 28298962 DOI: 10.4329/wjr.v9.i2.27]
Corresponding Author of This Article
Silvia Morbelli, MD, PhD, Nuclear Medicine Unit, IRCCS San Martino-IST, University of Genoa, Largo R. Benzi 10, 16132 Genova, Italy. silviadaniela.morbelli@hsanmartino.it
Research Domain of This Article
Radiology, Nuclear Medicine & Medical Imaging
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S. Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography? World J Radiol 2017; 9(2): 27-33 [PMID: 28298962 DOI: 10.4329/wjr.v9.i2.27]
World J Radiol. Feb 28, 2017; 9(2): 27-33 Published online Feb 28, 2017. doi: 10.4329/wjr.v9.i2.27
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?
Matteo Bauckneht, Roberta Piva, Gianmario Sambuceti, Francesco Grossi, Silvia Morbelli
Matteo Bauckneht, Roberta Piva, Gianmario Sambuceti, Silvia Morbelli, Nuclear Medicine Unit, IRCCS San Martino-IST, University of Genoa, 16132 Genoa, Italy
Francesco Grossi, Lung Cancer Unit, IRCCS San Martino-IST, University of Genoa, 16132 Genoa, Italy
Author contributions: Morbelli S conceived and designed the study; Bauckneht M and Morbelli S drafted the manuscript; Bauckneht M and Piva R prepared the tables and figures; Sambuceti G and Grossi F critically revised the manuscript; all the authors approved the final version of the paper.
Conflict-of-interest statement: The authors have no conflicts of interest related to this publication to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Silvia Morbelli, MD, PhD, Nuclear Medicine Unit, IRCCS San Martino-IST, University of Genoa, Largo R. Benzi 10, 16132 Genova, Italy. silviadaniela.morbelli@hsanmartino.it
Telephone: +39-010-5552026 Fax: +39-010-5556911
Received: August 20, 2016 Peer-review started: August 23, 2016 First decision: October 21, 2016 Revised: November 2, 2016 Accepted: November 27, 2016 Article in press: November 29, 2016 Published online: February 28, 2017 Processing time: 191 Days and 12 Hours
Core Tip
Core tip: In the clinical practice, the radiological interpretation of immunotherapy effects represents a huge challenge at single patient level. However, although the computed tomography-based response evaluation for immune checkpoint inhibitors (ICPIs) is feasible thanks to the introduction of immune-related response criteria, very few data are available for the potential role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET). Due to the intrinsic nature of FDG accumulation pathophysiology, it might be central to test the complex and variegated response to ICPIs by means of PET. Finally, PET might offer a new insight into the biology of ICPIs thanks to a growing number of non-invasive immune-diagnostic approaches based on non-FDG tracers.